Popular Weight-Loss Drug May Treat Obstructive Sleep Apnea: New Study

Tirzepatide, an antidiabetic and weight-loss medication marketed as Mounjaro and Zepbound, may reduce obesity, an underlying factor in sleep apnea.

Sleep apnea is more common among overweight people and those suffering from hypertension. Monkey Business Images/Shutterstock

Tirzepatide, a popular antidiabetic drug approved for chronic weight management, may also aid in treating obstructive sleep apnea (OSA) in obese patients, according to new research funded by the drug’s manufacturer, Eli Lilly and Company. 

Obstructive sleep apnea is a common breathing disorder affecting the upper airways. It causes people to experience breathing interruptions during sleep, resulting in impaired sleep quality, mental health problems, and an increased risk of cardiovascular disease.